Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

JNJ 98.94 +0.74 (0.75%)
price chart
J&J's Global Media Review Hits Halfway Mark
Johnson & Johnson is midway through a global review of its media planning and buying business with its decision in the North American market this week.
Johnson & Johnson Campaign for Nursing's Future turns 10
Ten years ago a nursing shortage loomed in the United States. A shortfall of about 400,000 nurses by 2020 was projected and, between 1983 and 1998, the proportion of RNs younger than 30 had dropped from 30% to 12%, according to a 2000 article in the ...
Johnson & Johnson Reaches Settlement in 845 Levaquin Cases
Nov. 1 (Bloomberg) -- Johnson & Johnson settled lawsuits with about 845 plaintiffs who claimed the drugmaker didn't properly warn of the risks of tendon damage from its antibiotic Levaquin.
J&J says it won't enforce AIDS drug patent in Africa
LONDON Generic manufacturers are to be given a free rein to make cheap copies of Johnson & Johnson's HIV/AIDS drug Prezista for sale in Africa and other poor countries.
J&J opens HIV fighter Prezista to copycats in poor countries  FiercePharma
Johnson & Johnson Elects CEO Gorsky Chairman
Johnson & Johnson (JNJ) said it elected new CEO Alex Gorsky as chairman on Friday, replacing Bill Weldon who will step down later this year with plans to retire in the first quarter of 2013.
Johnson & Johnson Chief Gorsky Elected to Chairman  Bloomberg
Weldon passes baton at Johnson & Johnson to Gorsky  Bizjournals.com
Dr. Buffett Has Diagnosed Johnson & Johnson As Too Big To Succeed
We are amazed that Johnson & Johnson's (NYSE:JNJ) shares have held up better than the S&P 500 over the last month.
Johnson & Johnson, Merck and Eli Lilly to rip red tape from clinical trials
Johnson & Johnson's ($JNJ) Janssen R&D unit is leading a charge to expedite the tedious process of selecting sites for clinical trial sites, with the creation of a investigator database intended to get studies up and running more efficiently.
J&J, Lilly, Merck plan clinical trial site database  Reuters
Johnson & Johnson One-Ups Tuberculosis
In an 18-0 ruling on efficacy, the FDA advisory committee voted in favor of Johnson & Johnson's bedaquiline, a drug to combat multidrug-resistant tuberculosis.
Johnson & Johnson Is Undervalued — Here's Why
The reason behind this perceived overvaluation of Johnson & Johnson is the fact that there were a few one-time charges against earnings, which decreased them.
Johnson & Johnson Settles 845 Levaquin Tendon Rupture Lawsuits
Johnson & Johnson (JNJ) recently settled personal injury and product liability claims with about 845 plaintiffs. The plaintiffs alleged in their lawsuits that the drug manufacturer did not adequately warn of the risks of tendon damage and tendon ...
J&J settles a boatload of Levaquin cases  FiercePharma